Thursday, February 18, 2021 1:10:29 PM
February 18 2021 - 08:05AM
GlobeNewswire Inc.
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its fourth quarter and full year 2020 financial and operating results after the close of U.S. financial markets on Thursday, February 25, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
Conference call and webcast:
Date: February 25, 2021
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Dial-in: (855) 779-9066 (Domestic) or (631) 485-4859 (International)
Passcode: 5681569
Via web: www.traconpharma.com; “Events and Presentations” section within the “Investors” section
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
Company Contact: Investor Contact:
Mark Wiggins Brian Ritchie
Chief Business Officer LifeSci Advisors LLC
(858) 251-3492 212-915-2578
mwiggins@traconpharma.com
Recent TCON News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 10:03:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 10:00:35 PM
- TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 • GlobeNewswire Inc. • 02/28/2024 09:02:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:31:59 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 10:00:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 10:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 01:05:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:11:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:01:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:12:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/07/2023 09:02:56 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/25/2023 09:19:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 12:08:13 PM
- TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023 • GlobeNewswire Inc. • 05/03/2023 08:02:00 PM
- Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update • GlobeNewswire Inc. • 04/06/2023 12:30:47 PM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM